Hana Safah, MD

Articles

Supportive Care and Medication Access in GvHD

March 27th 2024

Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.

Therapies in Development for Chronic GvHD

March 20th 2024

Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.

Approved Therapies for Steroid-Refractory Chronic GvHD

March 20th 2024

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Treating Patients With Steroid-Refractory Chronic GvHD

March 13th 2024

Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.

First-Line Therapy for Chronic GvHD

March 13th 2024

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Staging Practices for Chronic Graft-vs-Host Disease

March 6th 2024

Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.

Role of Biomarkers in Graft-vs-Host Disease

March 6th 2024

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

How Does GvHD Typically Present?

February 28th 2024

Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.

Overview of Graft-vs-Host Disease (GvHD)

February 28th 2024

Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

March 13th 2023

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Does Belantamab Have a Place in Multiple Myeloma Treatment?

March 13th 2023

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Preventing Infection in Patients with Multiple Myeloma During Treatment

March 13th 2023

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

March 6th 2023

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Targets in Multiple Myeloma: FcRH5

March 6th 2023

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Targets in Multiple Myeloma: GPRC5D

February 27th 2023

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Data Updates on Immunotherapy Combinations in Multiple Myeloma

February 27th 2023

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Retreatment with a BCMA-Targeting Bispecific for R/R MM

February 20th 2023

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

February 20th 2023

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

February 13th 2023

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

February 13th 2023

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.